Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29    OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.

Neueste

  • Neue Fortschritte bei der Untersuchung des Mechanismus von Lianhua Qingwen-Kapseln zur Behandlung von COVID-19

    ​Kürzlich haben Prof. Caisheng Wu und Prof. Yifeng Chai von der School of Pharmacy, Xiamen University neue Fortschritte bei der Untersuchung der pharmakologisch aktiven Inhaltsstoffe und des Mechanismus von Lianhua Qingwen Kapseln bei der Prävention und Behandlung von COVID-19 gemacht. Das Ergebnis der Studie, "Screening of the Anti-COVID-19 Pharmacological Active Ingredients of Traditional Chines
  • Yutong совместно с компанией Mowasalat обслуживает Клубный чемпионат мира по футболу 2020 в Катаре

    4 февраля 2021 года в Катаре официально начался 17-й Клубный чемпионат мира по футболу ФИФА, в рамках которого в городе Доха собрались ведущие футбольные клубы из 5 континентов. Среди них такие звездные команды, как победитель Лиги чемпионов УЕФА — германский футбольный клуб «Бавария» и местный клуб Аль-Духайль. В чемпионате также приняли участие такие команды, как Палмейрас из Бразилии, Ульсан Хё
  • Equipped with UNISOC T618, ZTE Axon 20 4G with Under-Screen Camera Has Been Launched Overseas

    Shanghai, China, December X, 2020 - The 4G version of the flagship ZTE cellphone, the Axon 20 4G, with an under-screen camera, powered by a UNISOC T618 chipset, which is an 8-core CPU, is announced to be launched on the overseas markets such as Germany and Mexico.
  • The world’s first 4G camera-under-screen cellphone represents the coming era of the real full-screen cellphone

    The under-screen camera and the extremely narrow border can provide its users with bigger game graphics, and the length-to-width ratio is close to that of the movie screen-all bringing shocking visual effects.
  • BYD Wins the Largest Pure-Electric Bus Order outside of China

    Bogotá, Colombia - BYD is proud to announce that it has exclusively won cumulative orders to supply 1,002-unit pure-electric buses to the capital of Colombia, Bogotá. This tender was open to all bus technologies, yet BYD won the trust and cooperation of its partners in the fiercely competitive bidding process thanks to its cutting-edge technologies, products and services. This is the largest order
  • Dab the 5G Era with the Perfume of Books and Fragrance of Ink — allow full rein to a better life with Hisense A7

    On Dec 22nd, Hisense’s new reading flagship cellphone A7 series was officially launched. This series is the continuation of the characteristics of Hisense A series' most typical ink screen design, namely e-ink screen, a kind of screen that uses electronic ink, which is also known as e-paper displays. This is the world's first 5G cellphone equipped with an ink screen, marking the official arrival o
  • BYD Delivers Largest Pure Electric Bus Fleet in Colombia

    Bogota, Colombia - On December 17, BYD announced the delivery of 470 pure electric buses to Bogota, the capital of Colombia. This is the country’s largest pure electric bus fleet, and also the largest bus fleet BYD has delivered in the Americas, which will effectively promote the already fast-growing electrified public transport systems in Colombia, Latin America and the entire Americas.
  • UNISOC and CTTL Helped Fibocom to Obtain the World's First Cat.1bis Module GCF Certification

    On December 21, 2020, UNISOC, China Telecommunication Technology Labs (CTTL) and Fibocom jointly announced that Fibocom L610-EU module was officially awarded the world's first 3GPP UE category 1bis module (Cat.1bis for short) GCF/CE/NCC certification, which marked that the Fibocom Cat.1bis module equipped with the UNISOC 8910DM chip has the overseas supply capacity officially.
  • New Sapphire Timepiece by AET REMOULD - Sapphire Daytona

    On Christmas Eve, AET REMOULD specially launched the sapphire Daytona Xmas, which uses AET REMOULD's iconic sapphire crystal material and creates a brand new sapphire crystal Daytona.
  • Industry's First 5G Terminal Slicing Solution Demonstrated

    SHANGHAI, Dec 4, 2020 - UNISOC, with China Mobile, ZTE and other industry chain partners, jointly completed an application demonstration of the world's first 5G terminal slicing target solution, which indicates that 5G terminal has been equipped with the slicing capability and can provide personalized and customized services for 5G users. The demonstration took place at the 8th China Mobile Globa

Link

Back to top
© Urheberrechte 2009-2020 Auto täglich      Kontaktieren Sie Uns   SiteMap